Table 2.
Team | Year | Region | Tumor Type | Cell Line | Tumor Model | CAR | Contrast | Application | Results | Ref. |
---|---|---|---|---|---|---|---|---|---|---|
Priceman et al. | 2018 | USA | Breast | Human breast cancer | Xenotransplant models in mice | HER2-BBζ |
HER2-28ζ Mock |
In vitro i.c i.c.v |
HER2-BBζ: cytokine production ↓, T cell exhaustion phenotype ↓, proliferative capacity ↑; i.c.: significant antitumor responses, extend survival; i.c.v.: treating multifocal BM evidence |
[180] |
Li et al | 2022 | CHN & USA | Lung | Human NSCLC | Xenotransplant models in mice | B7-H3 co-expressed CCR2b | B7-H3 without co-expression | Intravenous |
significant antitumor activity; more tumor-specific enhanced infiltration |
[170] |
Subham et al | 2022 | USA | Breast | Human TNBC | Xenotransplant models in mice | EGFR806 | Mock |
In vitro i.c |
effectively kill tumor in vitro; i.c.: effective tumor regression, statistically significant survival |
[181] |
Xu et al | 2023 | DEU | Lung | Murine Lewis Lung carcinoma | Intraparenchymal models in mice | Anti-EpCAM | – | Local vs i.v |
local: significant decreased brain tumor growth; i.v.: no anti-tumorous evidence; |
[182] |
NSCLC, non-small cell lung cancer; TNBC, triple-negative breast cancer; i.c., intratumoral/intracranial; i.c.v., intraventricular/intracerebroventricular; i.v., intravenous